Fatty acid synthase inhibition by amentoflavone suppresses HER2/neu (erbB2) oncogene in SKBR3 human breast cancer cells

Phytotherapy Research

Volumn 27, Issue 5, 2013, Pages 713-720

  Lee, Jin Sun ^a   Sul, Ji Young ^a   Park, Jun Beom ^a   Lee, Myung Sun ^a   Cha, Eun Young ^a   Song, In Sang ^a   Kim, Je Ryong ^a   Chang, Eil Sung ^a  

^a Chungnam National University College of Medicine   (South Korea)

Author keywords

amentoflavone; breast cancer; fatty acid synthase; HER2 neu

Indexed keywords

AMENTOFLAVONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FATTY ACID SYNTHASE; FATTY ACID SYNTHASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PALMITIC ACID; PROTEIN KINASE B; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR PEA3;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE REPRESSION; HUMAN; HUMAN CELL; ONCOGENE NEU; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIFLAVONOIDS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; FATTY ACID SYNTHETASE COMPLEX; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PHOSPHORYLATION; RECEPTOR, ERBB-2;

EID: 84876462441     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.4778     Document Type: Article

References (34)

1. Alò PL, Visca P, Trombetta G, et al,. 1999. Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas. Tumori 85: 35-40.
2. Carter P, Fendly BM, Lewis GD, et al,. 2000. Development of herceptin. Breast Dis 11: 103-111.
3. Chiang CT, Way TD, Tsai SJ, et al,. 2007. Diosgenin, a naturally occurring steroid, suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt, mTOR and JNK phosphorylation. FEBS Lett 581: 5735-5742.
4. Guruvayoorappan C, Kuttan G,. 2007. Effect of amentoflavone on the inhibition of pulmonary metastasis induced by B16F-10 melanoma cells in C57BL/6 mice. Integr Cancer Ther 6: 185-197.
5. Guruvayoorappan C, Kuttan G,. 2008a. Amentoflavone stimulates apoptosis in B16F-10 melanoma cells by regulating bcl-2, p53 as well as caspase-3 genes and regulates the nitric oxide as well as proinflammatory cytokine production in B16F-10 melanoma cells, tumor associated macrophages and peritoneal macrophages. J Exp Ther Oncol 7: 207-218.
6. Guruvayoorappan C, Kuttan G,. 2008b. Amentoflavone inhibits experimental tumor metastasis through a regulatory mechanism involving MMP-2, MMP-9, prolyl hydroxylase, lysyl oxidase, VEGF, ERK-1, ERK-2, STAT-1, nm23 and cytokines in lung tissues of C57BL/6 mice. Immunopharmacol Immunotoxicol 30: 711-727.
7. Guruvayoorappan C, Kuttan G,. 2008c. Inhibition of tumor specific angiogenesis by amentoflavone. Biochemistry (Mosc) 73: 209-218.
8. Kuhajda FP,. 2002. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 66: 5977-5980.
9. Kumar-Sinha C, Ignatoski KW, Lippman ME, et al,. 2003. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 63: 132-139.
10. Lee JS, Lee MS, Oh WK, et al,. 2009. Fatty acid synthase inhibition by amentoflavone induces apoptosis and antiproliferation in human breast cancer cells. Biol Pharm Bull 32: 1427-1232.
11. Maier T, Jenni S, Ban N,. 2006. Architecture of mammalian fatty acid synthase at 4.5 A resolution. Science 311: 1258-1262.
12. Ménard S, Pupa SM, Campiglio M, et al,. 2003. Biologic and therapeutic role of HER2 in cancer. Oncogene 22: 6570-6578.
13. Menendez JA,. 2010. Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: Molecular mechanisms and therapeutic perspectives. Biochim Biophys Acta 1801: 381-391.
14. Menendez JA, Vellon L, Lupu R,. 2005a. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann Oncol 16: 1253-1267.
15. Menendez JA, Vellon L, Lupu R,. 2005b. Orlistat: from antiobesity drug to anticancer agent in Her-2/neu (erbB-2)-overexpressing gastrointestinal tumors? Exp Biol Med 230: 151-154.
16. Menendez JA, Vellon L, Lupu R,. 2005c. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. Med Hypotheses 64: 997-1001.
17. Menendez JA, Vellon L, Mehmi I, et al,. 2004. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA 101: 10715-10720.
18. Nahta R, Yu D, Hung MC, et al,. 2006. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3: 269-280.
19. Pizer ES, Jackisch C, Wood FD, et al,. 1996. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res 56: 2745-2747.
20. Puig T, Vázquez-Martín A, Relat J, et al,. 2008. Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. Breast Cancer Res Treat 109: 471-479.
21. Rawson RB,. 2003. The SREBP pathway - insights from Insigs and insects. Nat Rev Mol Cell Biol 4: 631-640.
22. Sul HS, Smas CM, Wang D, et al,. 1998. Regulation of fat synthesis and adipose differentiation. Prog Nucleic Acid Res Mol Biol 60: 317-345.
23. Swinnen JV, Roskams T, Joniau S, et al,. 2002. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 98: 19-22.
24. Vazquez-Martin A, Fernandez-Real JM, Oliveras-Ferraros C, et al,. 2009. Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients. Int J Oncol 35: 1369-1376.
25. Wang Y, Ye L, Leung LK,. 2008. A positive feedback pathway of estrogen biosynthesis in breast cancer cells is contained by resveratrol. Toxicology 248: 130-135.
26. Weng MS, Ho CT, Ho YS, et al,. 2007. Theanaphthoquinone inhibits fatty acid synthase expression in EGF-stimulated human breast cancer cells via the regulation of EGFR/ErbB-2 signaling. Toxicol Appl Pharmacol 218: 107-118.
27. Xing X, Wang SC, Xia W, et al,. 2000. The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat Med 6: 189-195.
28. Yang YA, Han WF, Morin PJ, et al,. 2002. Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res 279: 80-90.
29. Yang YA, Morin PJ, Han WF, et al,. 2003. Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res 282: 132-137.
30. Yeh CW, Chen WJ, Chiang CT, et al,. 2003. Suppression of fatty acid synthase in MCF-7 breast cancer cells by tea and tea polyphenols: a possible mechanism for their hypolipidemic effects. Pharmacogenomics J 3: 267-276.
31. Yoon S, Lee MY, Park SW, et al,. 2007. Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. J Biol Chem 282: 26122-26131.
32. Zhang D, Tai LK, Wong LL, et al,. 2005. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics 4: 1686-1696.
33. Zhao W, Kridel S, Thorburn A, et al,. 2006. Fatty acid synthase: a novel target for antiglioma therapy. Br J Cancer 95: 869-878.
34. Zhou X, Tan M, Stone Hawthorne V, et al,. 2004. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10: 6779-6788.